Neoadjuvant Tyrosine Kinase Downstaging of T2 Renal Cell Carcinoma in Solitary Kidney Before Robotic Partial Nephrectomy | Zendy

Mary K. Powers | Zendy; Oliver Sartor | Zendy; Benjamin R. Lee | Zendy

Open Access

Neoadjuvant Tyrosine Kinase Downstaging of T2 Renal Cell Carcinoma in Solitary Kidney Before Robotic Partial Nephrectomy

Author(s) -

Mary K. Powers,

Oliver Sartor,

Benjamin R. Lee

Publication year - 2015

Publication title -

journal of endourology case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.123

H-Index - 1

ISSN - 2379-9889

DOI - 10.1089/cren.2015.0005

Subject(s) - pazopanib , medicine , nephrectomy , renal cell carcinoma , tyrosine kinase inhibitor , tyrosine kinase , kidney , clear cell renal cell carcinoma , urology , sunitinib , oncology , cancer , receptor

We highlight the use of a tyrosine kinase inhibitor, pazopanib, for neoadjuvant downstaging a 7.4 cm right biopsy-proven clear cell renal-cell carcinoma in a solitary kidney before surgical intervention of robotic partial nephrectomy with retrograde cooling to induce cold ischemia in a 79-year-old male.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research